USE OF MESO- AND NANOPOROUS MATERIAL FOR SURFACTANT TRAPPING IN NANOPARTICLE SUSPENSIONS
Disclosed are methods of making stable nanoparticle suspensions wherein one or more nanoporous or mesoporous materials are used to absorb and remove one or more non-tolerated surfactants from the nanoparticle suspensions. Also provided are methods of making stable nanoparticle suspension formulations wherein one or more macromolecular or colloidal stabilizers or tolerated surfactants are simultaneously added to further stabilize the nanoparticle suspension formulation. Thus to prevent a collapse of the suspension, one exchanges or replaces the surfactants that are not tolerated, by one or more tolerated surfactants or by macro-molecular/colloidal stabilizers.
1 . A method of making a stable nanoparticle suspension of a poorly soluble active ingredient, comprising:
preparing the nanoparticle suspension;
adding at least one surfactant to stabilize the nanoparticle suspension; and
removing essentially all non-tolerated surfactants from the nanoparticle suspension.
2 . The method of claim 1 , wherein preparing the nanoparticle suspension comprises milling, precipitation, spray drying, spray chilling, and combinations thereof.
3 . The method of claim 1 , wherein adding the at least one surfactant comprises adding a surfactant cocktail to stabilize a high surface area of the nanoparticle suspension.
4 . The method of claim 1 , wherein a maximum wetting of a poorly soluble material by an aqueous medium is achieved by the surfactant or surfactant cocktail.
5 . The method of claim 1 , wherein to prevent a collapse of the suspension, the one or more non-tolerated surfactants is exchanged or replaced with one or more tolerated surfactants or macromolecular/colloidal stabilizers.
6 . The method of claim 1 , wherein one or more macromolecular or colloidal stabilizers or tolerated surfactants are simultaneously added to further stabilize the nanoparticle suspension formulation.
7 . The method of claim 1 , wherein the removal from the suspension of non-tolerated surfactants comprises adding one or more nanoporous or mesoporous materials to adsorb and remove one or more non-tolerated surfactants from the nanoparticle suspension.
8 . The method of claim 7 , wherein the stable nanoparticle suspension comprises a plurality of anionic mesoporous nanoparticles.
9 . The method of claim 7 , wherein the stable nanoparticle suspension comprises a plurality of cationic mesoporous nanoparticles.
10 . The method of claim 7 , wherein the one or more nanoporous or mesoporous materials comprises at least one of neusilin, mesoporous materials MCM 41 (anionically and cationically equipped), titanium dioxide, silica gel, gamma aluminium oxide, bentonite, zeolite, calcium carbonate, or any combination thereof.
11 . The method of claim 7 , wherein the one or more nanoporous or mesoporous materials adsorb low-molecular weight surfactants but not the macromolecular or colloidal stabilizers or the poorly soluble active ingredient.
12 . The method of claim 7 , wherein the one or more mesoporous materials comprise mesoporous structures having pore sizes ranging from about 2 nm to about 50 nm.
13 . The method of claim 1 , wherein the poorly soluble active ingredient is selected from the group consisting of acyclovir, acrivastine, aceclofenac, acetaminophen paracetamol), adriamycin, albendazole, acetazolamide, acetylsalicylic acid, albuterol, allopurinol, amlodipine, amoxicillin, amphetamine, azathioprine, azelastine, amphotericin B, angiotensin converting enzyme (ACE) or NET inhibitors, atorvastatin, allopurinol, 1-carbocysteine, aluminium hydroxide, amoxicillin, atovaquone, azithromycin, baclofen, benidipine, bicalutamide, busulfan, bisacodyl, cabergoline, butenafine, calcipotriene, calcitriol, camptothecin, cannabinoids, capsaicin, carbamazepine, carotenes, cefdinir, cefditoren pivoxil, cefixime, celecoxib, cerivastatin, cefotiam hexetil hydrochloride, cefpodoxime proxetil, cefuroxime axetil, cetirizine, candesartan cilexetil, chloroquine, chlorpromazine, cilostazol, carvedilol, chlorpheniramine, cimetidine, ciprofloxacin, cisapride, clarithromycin, clemastine, codeine, cyclosporine, clofazimine, clopidogrel, clozapine, cyproterone, dapsone, danazol, dantrolene, dexchlorpheniramine, dexamethasone, digoxin, dirithromycin, donepezil, dexamethasone, diazepam, diclofenac, diloxanide, doxycycline, ebastine, efavirenz, eprosartan and other sartans, epalrestat, ergotamines, esomeprazole, estrogens, etodolac, etoposide, erythromycin ethylsuccinate, ethyl icosapentate, ezetimibe, famotidine, fenofibrate, fibric acid derivatives, fentanyl, fexofenadine, finasteride, fluconazole, flurbiprofen, flutamide, fluvastatin, fosphenytoin, frovatriptan, famotidine, folic acid, furosemide, gabapentin, gemfibrozil, glibenclamide, glimepiride, gefitinib, gliclazide, glipizide, glyburide, griseofulvin, glibenclamide, haloperidol, hydrochlorothiazide, hydroxyzine, halofantrine, ibuprofen, pralnacasan, indomethacin, irinotecan, imatinib, indinavir, iopanoic acid, irbesartan, isotretinoin, isradipine, itraconazole, ivermectin, ketoconazole, ketoprofen, ketorolac, lamotrigine, lansoprazole, leflunomide, levodopa, levosulpiride, linezolid, loperamide, lopinavir, loratadine, lovastatin, lorazepam, lycopenes, manidipine, mebendazole, mefloquine, medroxyprogesterone, melphalan, meloxicam, mesalamine, menatetrenone, metaxalone, methadone, methoxsalen, metoclopramide, metronidazole, miconazole, midazolam, mifepristone, miglitol, mitoxantrone, modafinil, methylphenidate, mosapride, mycophenolate mofetil, nabumetone, nalbuphine, nalidixic acid, naproxen, naratriptan, nelfinavir, nevirapine, nicergoline, niclosamide, nifedipine, nilutamide, nizatidine, nilvadipine, nimesulide, nitrofurantoin, nystatin, olanzapine, orlistat, omeprazole, oxaprozin, oxcarbazepine, oxycodone, paclitaxel, pentazocine, phenytoin, phenobarbital, pioglitazone, pizotifen, pralnacasan, pranlukast, praziquantel, propylthiouracil, pravastatin, probucol, pyrantel, pyrimethamine, lansoprazole, pseudoephedrine, propylthiouracil, pyridostigmine, quetiapine, quinine, rabeprazole, raloxifene, repaglinide, rebamipide, retinol, rifampicin, rifapentine, rimexolone, risperidone, ritonavir, rizatriptan, rofecoxib, rosiglitazone, saquinavir, sibutramine, roxithromycin, sennosides, sildenafil citrate, simvastatin, sirolimus, spironolactone, steroids, sulfadiazine, sulfamethoxazole, sulfasalazine, sultamicillin sumatriptan, tacrine, tacrolimus, tamoxifen, telmisartan, teprenone, tamsulosin, targretin, tazarotene, teniposide, terbinafine, testosterones, tiagabine, ticlopidine, tocopherol nicotinate, tizanidine, theophylline, topiramate, topotecan, valproic acid, valsartan, toremifene, tosufloxacin, tramadol, tretinoin, trimethoprim, triflusal, troglitazone, trovafloxacin, verapamil, warfarin, ursodeoxycholic acid, verteporfin, vigabatrin, vitamin A, vitamin D, vitamin E, vitamin K, zaltoprofen, zafirlukast, zileuton, zolmitriptan, zolpidem, zopiclone, or pharmaceutically acceptable salts, isomers, prodrugs and derivatives thereof, and any combination thereof.
14 . The method of 3 , wherein a bioavailability of the poorly soluble active ingredient is increased with the stable nanoparticle suspension.